Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK101 for Moderate to Severe Plaque Psoriasis – Long-term Safety and Efficacy (China, Phase 3 Extension)
CTR20220206Phase 3Completed
- Sponsor
- Akeso, Inc.
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of ebdarokimab in plaque psoriasis (2 arms), sponsored by Akeso, Inc. Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs) during the study. Started Jan 2022; status: completed.
02
Drugs
ebdarokimab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20220206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220206.